Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Earnings for Tango Therapeutics, Inc. (TNGX)
Earnings in 2023 (TTM): $-101,610,000
According to Tango Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-101,610,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Tango Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-101,610,000 | $-101,744,000 |
| 2022 | $-108,122,000 | $-108,176,000 |
| 2021 | $-57,943,000 | $-58,235,000 |
| 2020 | $-51,972,000 | $-51,864,000 |
| 2019 | $-14,095,000 | $-14,095,000 |